Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Iterum Therapeutics plcITRM · Entity 72802 | Chief Commercial Officer | July 01, 2025 | July 03, 2025 |
| SCYNEXIS INCSCYX · Entity 7194 | Chief Commercial Officer | February 04, 2022 | February 08, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Iterum Therapeutics plc
Report date July 01, 2025 · Filed July 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.97 · Expires 2035-06-30 | Direct | 200,000 |
Reported balance
After 2025-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-07-01 · Grant · Acquired 200,000 · Balance 200,000 F1: The shares underlying this option shall vest at a rate of twenty-five percent of the total number of shares on the one-year anniversary of July 1, 2025 and the remaining 75% will vest in equal monthly installments thereafter until July 1, 2029, subject to the Reporting Person providing continuous service to the Issuer on each relevant vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option shall vest at a rate of twenty-five percent of the total number of shares on the one-year anniversary of July 1, 2025 and the remaining 75% will vest in equal monthly installments thereafter until July 1, 2029, subject to the Reporting Person providing continuous service to the Issuer on each relevant vesting date.
SCYNEXIS INC
Report date February 04, 2022 · Filed February 08, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 58,200 |
Reported balance
After 2022-02-04 transaction · row 1
1 source rowRow 1 · 2022-02-04 · Grant · Acquired 43,200 · Balance 58,200 F1: Represents restricted stock units that vest 50% per year over two years on the anniversary of the date of grant. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.60 · Expires 2032-02-03 | Direct | 75,000 |
Reported balance
After 2022-02-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-02-04 · Grant · Acquired 75,000 · Balance 75,000 F2: 1/48th of the shares subject to the option vest monthly for 48 months as measured from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that vest 50% per year over two years on the anniversary of the date of grant.
F2: 1/48th of the shares subject to the option vest monthly for 48 months as measured from the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2025 Filed Jul 3, 2025 16:16 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | GrantShare Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $0.97 | $0.00 |
DisclosureSEC source: 0000950170-25-093872 · ownership.xml · derivative · entry 1 Coyne Christine · CIK 0001861840 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Ordinary Shares · 200,000 shares Expires 2035-06-30 F1 · derivative.exercise_date: The shares underlying this option shall vest at a rate of twenty-five percent of the total number of shares on the one-year anniversary of July 1, 2025 and the remaining 75% will vest in equal monthly installments thereafter until July 1, 2029, subject to the Reporting Person providing continuous service to the Issuer on each relevant vesting date. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 21:12 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $4.60 | $0.00 |
DisclosureSEC source: 0001209191-22-007730 · doc4.xml · derivative · entry 2 Coyne Christine · CIK 0001861840 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2032-02-03 F2 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly for 48 months as measured from the date of grant. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 21:12 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantCommon Stock | 43,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-007730 · doc4.xml · nonDerivative · entry 1 Coyne Christine · CIK 0001861840 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,200 F1 · shares: Represents restricted stock units that vest 50% per year over two years on the anniversary of the date of grant. Read SEC document |
| May 10, 2021 Filed May 13, 2021 00:26 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $6.50 | $0.00 |
DisclosureSEC source: 0001209191-21-032231 · doc4.xml · derivative · entry 2 Coyne Christine · CIK 0001861840 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2031-05-09 F2 · derivative.exercise_date: 25% of the shares subject to this option vests on the one-year anniversary of the grant date with the remainder vesting in equal monthly installments for thirty-six (36) months thereafter, provided the executive continues to provide continuous services to us. Read SEC document |
| May 10, 2021 Filed May 13, 2021 00:26 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-032231 · doc4.xml · nonDerivative · entry 1 Coyne Christine · CIK 0001861840 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · shares: Represents restricted stock units that vest 25% per year over four years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.